LR 19021
Alternative Names: LB-54640; LR-19021Latest Information Update: 13 Mar 2024
At a glance
- Originator LG Chem
- Developer Rhythm
- Class Obesity therapies; Small molecules
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 29 Feb 2024 Phase-II clinical trials in Obesity (In adolescents, In adults, In the elderly) in USA, Europe, United Kingdom, France (PO) (NCT06046443) (NCT06041841)
- 04 Jan 2024 LG Chem and Rhythm Pharmaceuticals enter into a Licensing agreement for LB 54640
- 04 Jan 2024 Efficacy and adverse event data from a phase I trial in Obesity released by Rhythm Pharmaceuticals